- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 26.03. | US FDA grants orphan drug status to Palatin's obesity treatment PL7737 | ||
| 25.03. | NeuroNOS secures funding for autism treatment development | ||
| 24.03. | Duke-NUS and NUS Medicine launch centre for metabolomics research | ||
| 21.03. | FDA approves Novartis' Fabhalta for C3 glomerulopathy treatment | ||
| 20.03. | Porton Advanced and Eureka to expedite T-cell therapy development | ||
| 19.03. | Delpharm plans $140m investment to upgrade Boucherville facility in Canada | ||
| 18.03. | Health Canada approves Arcutis' roflumilast cream 0.15% for atopic dermatitis | ||
| 17.03. | FDA grants orphan drug status for Korro Bio's AATD therapy | ||
| 14.03. | FDA clears PDS Biotechnology's Versamune MUC1 combo for mCRC | ||
| 13.03. | LGM Pharma to expand manufacturing capabilities with $6m investment | ||
| 12.03. | Aprea and MD Anderson sign agreement for APR-1051 | ||
| 11.03. | Vivus' Qsymia gains market approval in UAE for obesity treatment | ||
| 10.03. | UK MHRA approves Vertex's Alyftrek for cystic fibrosis | ||
| 07.03. | Relief Therapeutics and Renexxion terminate merger talks | ||
| 06.03. | CordenPharma announces $1bn investment in peptide development and production | ||
| 05.03. | FairJourney acquires Charles River's San Francisco site | ||
| 04.03. | FDA approves Celltrion's biosimilars for various indications | ||
| 03.03. | EMA's CHMP recommends marketing authorisation for Novartis' Fabhalta | ||
| 28.02. | FDA grants fast track status for Avobis' AVB-114 | ||
| 27.02. | China's NMPA approves Fosun's NDA of Tenapanor Hydrochloride tablets | ||
| 26.02. | Health Canada grants marketing authorisation to Kashiv's Pegfilgrastim | ||
| 25.02. | Biocon Biologics launches ustekinumab biosimilar in US | ||
| 24.02. | Tiziana Life Sciences partners with Renaissance for intranasal foralumab production | ||
| 21.02. | Genmab's epcoritamab gains approval in Japan for lymphoma treatment | ||
| 20.02. | Nona Biosciences partners with UAB to advance B Cell research |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .